|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.41 CNY | +10.04% |
|
+4.83% | -14.32% |
| 05-22 | Zhuhai Rundu Pharmaceutical Wins China Approval for Pain Relief Drug | MT |
| 05-19 | China Grants Zhuhai Rundu Pharmaceutical Marketing Approval for Hypertension Drug | MT |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Chemical Pharmaceutical Manufacturing | 767M | 861M | 785M | 683M | 649M | |||||
Gross Profit | - | - | - | - | - | |||||
Manufacturing of Active Pharmaceutical Ingredients | 421M | 502M | 497M | 494M | 509M | |||||
Gross Profit | - | - | - | - | - | |||||
Unallocated Other Operations | 1.98M | 9.01M | 10.06M | 5.53M | 18.08M | |||||
R&D Service Income | - | - | - | - | - | |||||
Medicine within Body | - | - | - | - | - | |||||
Gross Profit | - | - | - | - | - |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
East China | 303M | 357M | 343M | 363M | 326M | |||||
South China | 312M | 315M | 260M | 232M | 236M | |||||
Central China | 150M | 191M | 193M | 186M | 179M | |||||
Export | 96.11M | 156M | 153M | 139M | 174M | |||||
Southwest China | 138M | 138M | 156M | 144M | 131M | |||||
North China | 115M | 124M | 91.3M | 61.16M | 72.29M | |||||
Northwest China | 47.81M | 57.07M | 61.06M | 41.96M | 44.08M | |||||
Northeast | 25.55M | 25.29M | 24M | 15.02M | 14.54M | |||||
Unallocated Other Business | 1.98M | 9.01M | 10.06M | - | - |
Select your edition
All financial news and data tailored to specific country editions
